November 23, 2020 11:07 AM EST
News Briefing

News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for $98M

Amber Tong

Max Gelman

Senior Editor

Teneo­bio may be best known for its pact with Ab­b­Vie and Gilead, but be­fore its big break the bis­pe­cif­ic play­er had li­censed its an­ti­bod­ies for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Biotech VC firm out­lines plans for $100M fund

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times